Craig-Hallum Maintains Buy on Cellebrite DI, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Jeff Van Rhee maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $20 to $23.
September 25, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum analyst Jeff Van Rhee has reaffirmed a Buy rating for Cellebrite DI and increased the price target from $20 to $23, indicating a positive outlook.
The reaffirmation of a Buy rating and an increase in the price target from $20 to $23 by Craig-Hallum suggests a positive outlook for Cellebrite DI. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100